Compare OOMA & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | VSTM |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.2M | 470.7M |
| IPO Year | 2015 | 2011 |
| Metric | OOMA | VSTM |
|---|---|---|
| Price | $14.41 | $5.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $18.77 | $15.25 |
| AVG Volume (30 Days) | 232.2K | ★ 2.1M |
| Earning Date | 05-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 188.46 | 17.49 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $114,490,000.00 | $30,914,000.00 |
| Revenue This Year | $20.35 | $282.64 |
| Revenue Next Year | $3.82 | $72.25 |
| P/E Ratio | $63.65 | ★ N/A |
| Revenue Growth | 9.53 | ★ 209.14 |
| 52 Week Low | $9.79 | $4.01 |
| 52 Week High | $15.15 | $11.25 |
| Indicator | OOMA | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 58.68 | 46.19 |
| Support Level | $10.95 | $4.80 |
| Resistance Level | $14.83 | $6.79 |
| Average True Range (ATR) | 0.50 | 0.41 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 56.32 | 51.91 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.